Compounds > paroxetine

Page last updated: 2024-08-23

paroxetine and Neuroleptic Malignant Syndrome

paroxetine has been researched along with Neuroleptic Malignant Syndrome in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (45.45)	18.2507
2000's	6 (54.55)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Christodoulou, GN; Havaki-Kontaxaki, BJ; Katritsis, DE; Kontaxakis, VP; Pappa, DA	1
Kashima, N; Nishimura, H	1
Fujita, K; Ichihashi, K; Inoue, K; Okazaki, Y; Tanii, H	1
Bernabei, R; Capurso, S; Gambassi, G; Liperoti, R; Tarsitani, P	1
Hamada, Y; Inatsugi, Y; Kusunoki, S; Miyamoto, K; Suzuki, H	1
Preskorn, SH	1
Sitarz, WE	1
Young, C	1
König, F; Löble, M; Wolfersdorf, M	1
Assion, HJ; Ehrlich, M; Heinemann, F; Hermes, G	1
Preskorn, SH; Shad, MU	1

Other Studies

11 other study(ies) available for paroxetine and Neuroleptic Malignant Syndrome

Article	Year
Neuroleptic malignant syndrome after addition of paroxetine to olanzapine. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:6 Topics: Benzodiazepines; Drug Therapy, Combination; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Olanzapine; Paroxetine; Selective Serotonin Reuptake Inhibitors	2003
[A case of probable neuroleptic malignant syndrome induced by monotherapy with paroxetine]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 2004, Volume: 106, Issue:6 Topics: Antidepressive Agents, Second-Generation; Diagnosis, Differential; Female; Fluid Therapy; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Paroxetine	2004
Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam. Progress in neuro-psychopharmacology & biological psychiatry, 2006, Aug-30, Volume: 30, Issue:6 Topics: Aged; Alprazolam; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Therapy, Combination; Humans; Hypnotics and Sedatives; Male; Neuroleptic Malignant Syndrome; Paroxetine; Psychiatric Status Rating Scales	2006
Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. Aging clinical and experimental research, 2006, Volume: 18, Issue:3 Topics: Aged; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Fatal Outcome; Humans; Male; Neuroleptic Malignant Syndrome; Paroxetine; Selective Serotonin Reuptake Inhibitors	2006
[A case of Parkinson's disease with neuroleptic malignant syndrome induced by paroxetine]. Rinsho shinkeigaku = Clinical neurology, 2006, Volume: 46, Issue:8 Topics: Aged; Depression; Female; Humans; Neuroleptic Malignant Syndrome; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors	2006
Neuroleptic malignant syndrome resulting from a complex drug-drug interaction: "I don't see 'em!". Journal of psychiatric practice, 2007, Volume: 13, Issue:5 Topics: Benztropine; Bipolar Disorder; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lithium Compounds; Middle Aged; Neuroleptic Malignant Syndrome; Paroxetine; Perphenazine; Psychotropic Drugs; Trazodone	2007
Comment: delayed risperidone-induced neuroleptic malignant syndrome. The Annals of pharmacotherapy, 1996, Volume: 30, Issue:11 Topics: Antimanic Agents; Drug Interactions; Humans; Lithium Chloride; Neuroleptic Malignant Syndrome; Paroxetine; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists	1996
A case of neuroleptic malignant syndrome and serotonin disturbance. Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:1 Topics: Akathisia, Drug-Induced; Benztropine; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lithium Carbonate; Middle Aged; Neuroleptic Malignant Syndrome; Neurologic Examination; Paroxetine; Perphenazine; Receptors, Serotonin; Trazodone	1997
[Depressive stupor--malignant neuroleptic syndrome--serotonin syndrome. A case contribution to a difficult differential diagnosis]. Der Nervenarzt, 1996, Volume: 67, Issue:5 Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Benzamides; Depressive Disorder; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Haloperidol; Humans; Middle Aged; Moclobemide; Monoamine Oxidase Inhibitors; Neuroleptic Malignant Syndrome; Neurologic Examination; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Syndrome; Trimipramine	1996
[Paroxetine-induced neuroleptic malignant syndrome]. Der Nervenarzt, 1997, Volume: 68, Issue:8 Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Depressive Disorder; Drug Therapy, Combination; Hematoma, Subdural; Humans; Male; Neuroleptic Malignant Syndrome; Neurologic Examination; Paroxetine; Postoperative Complications; Schizophrenia; Schizophrenic Psychology; Suicide, Attempted	1997
Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome. Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:4 Topics: Antipsychotic Agents; Brain; Drug Interactions; Drug Therapy, Combination; Humans; Lithium Carbonate; Neuroleptic Malignant Syndrome; Paroxetine; Perphenazine; Selective Serotonin Reuptake Inhibitors; Trazodone	1998